"The clinical promise of pocenbrodib, our potential best-in-class CBP/p300 inhibitor, lies not only in its remarkable efficacy in resistant prostate cancer models, but also in our sophisticated ...

Azul S.A. (NYSE:AZUL – Get Free Report) has received an average recommendation of “Hold” from the ten analysts that are ...

Constellation Brands, Inc. (NYSE:STZ – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-one ...

Rob Isbitts explains why current market volatility underscores the importance of understanding indexation and algorithmic ...

Aflac's dividend growth is strong, but with a high valuation and limited potential returns at this point, I recommend waiting ...